Skip to main content
Clinical Trials/RBR-92vxxk6
RBR-92vxxk6
Recruiting
Phase 3

Randomized controlled clinical trial on the effect of Hyperbaric Oxygen Therapy (HBO) in non intubated COVID-19 hospitalized patients

Hospital Risoleta Tolentino Neves0 sitesAugust 16, 2021

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Coronavirus infections of unspecified location
Sponsor
Hospital Risoleta Tolentino Neves
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 16, 2021
End Date
May 31, 2022
Last Updated
2 years ago
Study Type
Intervention

Investigators

Eligibility Criteria

Inclusion Criteria

  • Patients over 18 years of age; diagnosis confirmed by laboratory tests or computed tomography (CT) of the chest compatible with COVID\-19; oxygen saturation below 93% in ambient air; respiratory frequency greater than or equal to 24 resp / min; without a significant commitment from other bodies or systems.

Exclusion Criteria

  • Hemodynamic instability, defined by mean arterial pressure less than 60 mmHg; respiratory failure requiring intubation; blood levels of TGO/TGP greater than 5 times the upper limit of normal; several chronic kidney diseases in stage 4; kidney disease requiring dialysis, that is, with eGFR (Estimated Glomerular Filtration Rate) less than 30 mL/min; transition planned to another hospital, other than a place of study, within 72 hours; infection with the human immunodeficiency virus under highly active antiretroviral therapy (HAART); history of severe depression or attempted suicide or current suicidal ideation; contraindications related to the administration of hyperbaric oxygen: pregnancy; breast\-feeding; untreated pneumothorax; use of adriblastine, cisplatin, doxorubicin and mafenide; topical use of iodine and / or petrolatum; advanced emphysema with CO2 retention; claustrophobia; other conditions identified by the hyperbarist team.

Outcomes

Primary Outcomes

Not specified

Similar Trials